Corient Private Wealth LLC Boosts Stock Holdings in Insulet Corporation $PODD

Corient Private Wealth LLC grew its stake in shares of Insulet Corporation (NASDAQ:PODD) by 35.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 14,595 shares of the medical instruments supplier’s stock after purchasing an additional 3,782 shares during the quarter. Corient Private Wealth LLC’s holdings in Insulet were worth $4,160,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of PODD. Sit Investment Associates Inc. increased its holdings in Insulet by 13.9% during the 4th quarter. Sit Investment Associates Inc. now owns 18,634 shares of the medical instruments supplier’s stock valued at $5,297,000 after purchasing an additional 2,277 shares during the period. MidFirst Bank purchased a new stake in Insulet in the 4th quarter worth approximately $394,000. Kera Capital Partners Inc. grew its position in shares of Insulet by 92.0% in the 4th quarter. Kera Capital Partners Inc. now owns 1,966 shares of the medical instruments supplier’s stock worth $559,000 after buying an additional 942 shares during the last quarter. Virtu Financial LLC increased its stake in shares of Insulet by 126.5% during the fourth quarter. Virtu Financial LLC now owns 4,628 shares of the medical instruments supplier’s stock valued at $1,315,000 after buying an additional 2,585 shares during the period. Finally, MV Capital Management Inc. purchased a new position in shares of Insulet during the fourth quarter valued at approximately $29,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Oppenheimer decreased their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Sanford C. Bernstein reduced their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Stifel Nicolaus decreased their price objective on shares of Insulet from $350.00 to $250.00 in a report on Thursday, May 7th. BTIG Research dropped their target price on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday, May 26th. Finally, Leerink Partners dropped their target price on shares of Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $238.67.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $158.25 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The business has a 50-day simple moving average of $159.09 and a two-hundred day simple moving average of $220.64. Insulet Corporation has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The firm has a market cap of $10.96 billion, a price-to-earnings ratio of 36.80, a price-to-earnings-growth ratio of 1.07 and a beta of 1.13.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the company posted $1.02 earnings per share. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.